Abstract
Chronic HIV-1 infection commonly affects behavioral, cognitive, and motor functions in the infected human host and is commonly referred to as HIV-1-associated neurocognitive disorders (HAND). This occurs, in measure, as a consequence of ingress of leukocytes into brain perivascular regions. Such cells facilitate viral infection and disease by eliciting blood–brain barrier and neuronal network dysfunctions. Previous works demonstrated that the endocannabinoid system modulates neuroimmunity and as such neuronal and glial functions. Herein, we investigated CB2R receptor expression in murine HIV-1 encephalitis (HIVE) and the abilities of a highly selective CB2R agonist, Gp1a, to modulate disease. HIV-1-infected human monocyte-derived macrophages were injected into the caudate and putamen of immunodeficient mice reconstituted with human peripheral blood lymphocytes (hu-PBL/HIVE). Brains of hu-PBL/HIVE mice showed microglial activation and increased expression of CB2R, but not CB1R or GPR55. Gp1a substantively reduced infiltration of human cells into the mouse brain and reduced HLA DQ activation. Gp1a down modulated CCR5 expression on human cells in the spleen with an increase in Fas ligand expression. Our results support the notion that CB2 receptor agonists may be a viable therapeutic candidate for HAND.
Similar content being viewed by others
References
Ances BM, Ellis RJ (2007) Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 27(1):86–92
Arevalo-Martin A, Garcia-Ovejero D, Gomez O, Rubio-Araiz A, Navarro-Galve B, Guaza C, Molina-Holgado E, Molina-Holgado F (2008) CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br J Pharmacol 153(2):216–225
Ashton JC, Glass M (2007) The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 5(2):73–80
Basavarajappa BS, Nixon RA, Arancio O (2009) Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. Mini Rev Med Chem 9(4):448–462
Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci 23(35):11136–11141
Benito C, Kim WK, Chavarria I, Hillard CJ, Mackie K, Tolon RM, Williams K, Romero J (2005) A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 25(10):2530–2536
Benito C, Nunez E, Pazos MR, Tolon RM, Romero J (2007a) The endocannabinoid system and Alzheimer’s disease. Mol Neurobiol 36(1):75–81
Benito C, Romero JP, Tolon RM, Clemente D, Docagne F, Hillard CJ, Guaza C, Romero J (2007b) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27(9):2396–2402
Berney T, Molano RD, Pileggi A, Cattan P, Li H, Ricordi C, Inverardi L (2001) Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes. Transplantation 72(1):133–140
Berrendero F, Sanchez A, Cabranes A, Puerta C, Ramos JA, Garcia-Merino A, Fernandez-Ruiz J (2001) Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41(3):195–202
Buckley NE (2008) The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 153(2):309–318
Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 35(17):3135–3141
Cabral GA, Griffin-Thomas L (2008) Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets 8(3):159–172
Cabral GA, Harmon KN, Carlisle SJ (2001) Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv Exp Med Biol 493:207–214
Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153(2):240–251
Centonze D, Rossi S, Finazzi-Agro A, Bernardi G, Maccarrone M (2007) The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. Int Rev Neurobiol 82:171–186
Correa F, Docagne F, Mestre L, Loria F, Hernangomez M, Borrell J, Guaza C (2007) Cannabinoid system and neuroinflammation: implications for multiple sclerosis. Neuroimmunomodulation 14(3–4):182–187
Cota M, Mengozzi M, Vicenzi E, Panina-Bordignon P, Sinigaglia F, Transidico P, Sozzani S, Mantovani A, Poli G (2000) Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. Proc Natl Acad Sci U S A 97(16):9162–9167
Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373(6513):438–441
Docagne F, Mestre L, Loria F, Hernangomez M, Correa F, Guaza C (2008) Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin Ther Targets 12(2):185–195
Eggert D, Dash PK, Serradji N, Dong CZ, Clayette P, Heymans F, Dou H, Gorantla S, Gelbard HA, Poluektova L et al (2009) Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. J Neuroimmunol 213(1-2):47–59
Eggert D, Dash PK, Gorantla S, Dou H, Schifitto G, Maggirwar SB, Dewhurst S, Poluektova L, Gelbard HA, Gendelman HE (2010) Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol 184(2):746–756
Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytle RD (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2:29
Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A (2003) Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lipopolysaccharide. Glia 41(2):161–168
Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232(1):54–61
Gendelman HE, Persidsky Y, Ghorpade A, Limoges J, Stins M, Fiala M, Morrisett R (1997) The neuropathogenesis of the AIDS dementia complex. Aids 11(Suppl A):35–45
Gendelman HE, Diesing S, Gelbard H, Swindells S (2004) The neuropathogenesis of HIV-1 infection. Elsevier, London, pp 95–116
Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ (1998) Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 103(2):335–342
Gonsiorek W, Hesk D, Chen SC, Kinsley D, Fine JS, Jackson JV, Bober LA, Deno G, Bian H, Fossetta J et al (2006) Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336. J Biol Chem 281(38):28143–28151
Gorantla S, Liu J, Sneller H, Dou H, Holguin A, Smith L, Ikezu T, Volsky DJ, Poluektova L, Gendelman HE (2007) Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. J Immunol 179(7):4345–4356
Gorin NC, Piantadosi S, Stull M, Bonte H, Wingard JR, Civin C (2002) Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood. J Hematother Stem Cell Res 11(2):277–292
Green DR, Droin N, Pinkoski M (2003) Activation-induced cell death in T cells. Immunol Rev 193:70–81
Hoffmann-Fezer G, Gall C, Zengerle U, Kranz B, Thierfelder S (1993) Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Blood 81(12):3440–3448
Huppes W, Fickenscher H, tHart BA, Fleckenstein B (1994) Cytokine dependence of human to mouse graft-versus-host disease. Scand J Immunol 40(1):26–36
Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A (1995) Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373(6513):444–448
Kaul M, Lipton SA (2006) Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 4(3):307–318
Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA (2005) HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 12(Suppl 1):878–892
Klein TW, Newton CA (2007) Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol 601:395–413
Kreitzer FR, Stella N (2009) The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther 122(2):83–96
Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis 19(1–2):96–107
Leonelli M, Torrao AS, Britto LR (2009) Unconventional neurotransmitters, neurodegeneration and neuroprotection. Braz J Med Biol Res 42(1):68–75
Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM (1998) CCR5 is characteristic of Th1 lymphocytes. Nature 391(6665):344–345
Lombard C, Nagarkatti M, Nagarkatti P (2007) CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 122(3):259–270
Lunn CA, Reich EP, Bober L (2006) Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets 10(5):653–663
Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L (2008) Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol 153(2):226–239
Mackie K, Stella N (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8(2):E298–E306
Marcondes MCG, Burudi EME, Huitron-Resendiz S, Sanchez-Alavez M, Watry D, Zandonatti M, Henriksen SJ, Fox HS (2001) Highly activated CD8+ T cells in the brain correlate with early central nervous system dysfunction in simian immunodeficiency virus infection. J Immunol 167(9):5429–5438
Marcondes MC, Phillipson CA, Fox HS (2003) Distinct clonal repertoire of brain CD8+ cells in simian immunodeficiency virus infection. AIDS 17(11):1605–1611
Mestre L, Docagne F, Correa F, Loria F, Hernangomez M, Borrell J, Guaza C (2009) A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 40(2):258–266
Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I, Falzoi M, Dessi C, Curzu MM, Chelucci G et al (2006) Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′, 4′-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1, 4-dihydroindeno[1, 2-c ]pyrazole-3-carboxamide. J Med Chem 49(25):7502–7512
Onaivi ES (2009) Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol 88:335–369
Ostrowski MA, Justement SJ, Catanzaro A, Hallahan CA, Ehler LA, Mizell SB, Kumar PN, Mican JA, Chun TW, Fauci AS (1998) Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 161(6):3195–3201
Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58(3):389–462
Patel KD, Davison JS, Pittman QJ, Sharkey KA (2010) Cannabinoid CB(2) receptors in health and disease. Curr Med Chem 17(14):1394–1410
Pearson T, Greiner DL, Shultz LD (2008) Humanized SCID mouse models for biomedical research. Curr Top Microbiol Immunol 324:25–51
Pino S, Brehm MA, Covassin-Barberis L, King M, Gott B, Chase TH, Wagner J, Burzenski L, Foreman O, Greiner DL et al (2010) Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. Methods Mol Biol 602:105–117
Piomelli D (2005) The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6(7):672–679
Poluektova LY, Munn DH, Persidsky Y, Gendelman HE (2002) Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol 168(8):3941–3949
Poluektova L, Gorantla S, Faraci J, Birusingh K, Dou H, Gendelman HE (2004a) Neuroregulatory events follow adaptive immune-mediated elimination of HIV-1-infected macrophages: studies in a murine model of viral encephalitis. J Immunol 172(12):7610–7617
Poluektova LY, Gorantla S, Gendelman HE (2004b) Studies of adaptive immunity in a murine model of HIV-1 encephalitis. In: Gendelman HE, Grant I, Lipton S, Swindells S (eds) Neurology of AIDS. Oxford University Press, Oxford
Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y (2005) Inhibition of indoleamine 2, 3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 106(7):2382–2390
Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, Strong R, Lutz B, Marsicano G, Roberts JL et al (2009) WIN55, 212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci 29(11):2177–2186
Puffenbarger RA, Boothe AC, Cabral GA (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29(1):58–69
Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101(4):746–754
Rock RB, Gekker G, Hu S, Sheng WS, Cabral GA, Martin BR, Peterson PK (2007) WIN55, 212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J Neuroimmune Pharmacol 2(2):178–183
Rostasy K, Monti L, Yiannoutsos C, Kneissl M, Bell J, Kemper TL, Hedreen JC, Navia BA (1999) Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex. Ann Neurol 46(2):207–216
Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA (2005) IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood 106(7):2433–2435
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152(7):1092–1101
Schneider MK, Gronvik KO (1995) Acute graft-versus-host reaction in SCID mice leads to an abnormal expansion of CD8+ V beta 14+ and a broad inactivation of donor T cells followed by a host-restricted tolerance and a normalization of the TCR V beta repertoire in the chronic phase. Scand J Immunol 41(4):373–383
Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101(1):87–98
Smith DG, Guillemin GJ, Pemberton L, Kerr S, Nath A, Smythe GA, Brew BJ (2001) Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J NeuroVirol 7(1):56–60
Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434(7034):782–786
Stella N (2009) Endocannabinoid signaling in microglial cells. Neuropharmacology 56(Suppl 1):244–253
Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76(6):969–976
Tary-Lehmann M, Lehmann PV, Schols D, Roncarolo MG, Saxon A (1994) Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras. J Exp Med 180(5):1817–1827
Thakur GA, Tichkule R, Bajaj S, Makriyannis A (2009) Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 19(12):1647–1673
Tournoy KG, Depraetere S, Pauwels RA, Leroux-Roels GG (2000) Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice. Clin Exp Immunol 119(1):231–239
Van Duyne R, Pedati C, Guendel I, Carpio L, Kehn-Hall K, Saifuddin M, Kashanchi F (2009) The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 6(1):76
Verlinden SF, Mulder AH, de Leeuw JP, van Bekkum DW (1998) T lymphocytes determine the development of xeno GVHD and of human hemopoiesis in NOD/SCID mice following human umbilical cord blood transplantation. Stem Cells 16(Suppl 1):205–217
Waksman Y, Olson JM, Carlisle SJ, Cabral GA (1999) The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 288(3):1357–1366
Xu H, Cheng CL, Chen M, Manivannan A, Cabay L, Pertwee RG, Coutts A, Forrester JV (2007) Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 82(3):532–541
Acknowledgments
Charles Kusinsky, Meghan Michalak, and Victoria Smith at the University of Nebraska Medical Center, Omaha, NE, are thanked for their help with the FACS analyses. We thank Jillian Braun, summer undergraduate student, for her assistance in data analyses. We thank Dr. Mamoru Ito at Central Institute of Experimental Animals, Kawasaki, Japan for providing Balb/c-Rag2−/−γc−/− mice. We also thank Robin Taylor of the University of Nebraska Medical Center for administrative assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gorantla, S., Makarov, E., Roy, D. et al. Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS. J Neuroimmune Pharmacol 5, 456–468 (2010). https://doi.org/10.1007/s11481-010-9225-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-010-9225-8